Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced key management appointments aimed at driving commercialization efforts. Terig Hughes is appointed Chief Financial Officer, alongside Gaetan Michel as Chief Operating Officer, Gael Forterre as Chief Commercial Officer, and Mark Eccleston as Chief Technology Officer. The company has opened a new manufacturing facility and secured approximately $4 million in non-dilutive funding. The leadership transitions come as VolitionRx shifts from R&D to a focus on market readiness for its cancer diagnostic products.
VolitionRx Limited (NYSE AMERICAN: VNRX) will be presenting live at VirtualInvestorConferences.com on February 4, 2021, at 12:00 PM EST. The session, led by Scott Powell, CFO, aims to engage investors with real-time Q&A opportunities. VolitionRx specializes in epigenetic blood tests to aid in diagnosing various cancers and diseases, utilizing Nucleosomics technology. Participants are encouraged to pre-register and check their systems to ensure smooth access. An archived version will be available post-event for those unable to attend live.
VolitionRx Limited (NYSE AMERICAN: VNRX) presented an abstract at the virtual WCLC lung cancer conference, showcasing Nu.Q™ assays' potential in diagnosing lung cancer. The interim analysis indicates that these assays can reduce unnecessary biopsies by 32% for non-cancerous nodules detected via low-dose computed tomography (LDCT). The study, led by Professor Chen Jin-Shing at National Taiwan University Hospital, involves 1,200 subjects and aims to differentiate between benign nodules and early-stage lung cancers. Results will be published later this year.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the opening of its new 10,000 square foot manufacturing facility, "Silver One," in Isnes, Belgium. This facility will enable Volition to produce critical raw materials and finished products, including the recently launched Nu.Q™ Vet Cancer Screening Test and a CE-marked blood cancer test. The investment of just over $1 million was mostly funded through non-dilutive sources. The new site aims to secure the supply chain and lower production costs, enhancing profitability.
VolitionRx Limited (NYSE AMERICAN: VNRX) has secured an additional $4 million in non-dilutive funding from the Walloon Region and Namur Invest in Belgium, bringing the total to approximately $15 million. The latest funding includes a $1.3 million grant and $2.7 million in loans, which will support various projects, including a new production facility and cancer-related research. CEO Cameron Reynolds expressed satisfaction with this development, highlighting its importance for ongoing projects and operations.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Dr. Tom Butera DVM to its Board of Directors effective December 1, 2020. Dr. Butera, an experienced healthcare leader, will serve on the Audit, Compensation, and Nominations and Governance Committees. His appointment coincides with the recent launch of Volition's Nu.Q™ Vet Cancer Screening Test, which aims to enhance cancer diagnostics in both humans and animals. The company focuses on developing cost-effective blood tests through its proprietary Nucleosomics™ technology, with R&D activities in Belgium and additional locations globally.
VolitionRx Limited (NYSE AMERICAN: VNRX) has launched its Nu.Q™ Vet Cancer Screening Test, now available for order by veterinarians in the U.S. This low-cost blood test targets older dogs, particularly breeds at higher cancer risk. With an estimated 77 million dogs in the U.S., the test offers potential revenue of $45 per test. It demonstrates 100% specificity, detecting 74% of lymphoma and 89% of hemangiosarcoma. Volition emphasizes the test's role in earlier cancer detection and improved pet care.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced that Dr. Mark Eccleston presented preliminary results on COVID-19 disease monitoring at the MEDICA LABMED FORUM. The studies show elevated circulating nucleosomes in symptomatic COVID-19 patients, leading to a novel patent for disease progression monitoring. Results from ongoing longitudinal studies are anticipated by year-end 2020. The company aims to help in the COVID-19 pandemic and other infections related to NETosis. Severe COVID-19 patients exhibited significantly higher nucleosome levels, indicating potential for using these markers in clinical diagnostics.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its third quarter 2020 results, highlighting significant advancements in its product launch and clinical programs. The Nu.Q™ Vet Cancer Screening Test is set to launch on November 30, 2020. The company is working with Diagnostic Oncology CRO LLC on a clinical trial for Non-Hodgkin's Lymphoma, expecting FDA submissions 10-12 months into the trial. Financially, cash equivalents rose to approximately $21 million, and a burn rate of $1.6-1.7 million per month is noted. The company anticipates substantial revenue potential from its veterinary diagnostics.
VolitionRx Limited (NYSE AMERICAN: VNRX) has released a report titled A Look to the Future of Cancer Diagnostics, featuring insights from leading veterinary oncology experts. This report highlights the significance of early cancer detection and the introduction of the Nu.Q™ Vet Cancer Screening Test. The test aims to streamline the diagnostic process for canine cancers, including lymphoma and hemangiosarcoma, using a simple blood sample. The report emphasizes the potential benefits of early detection for improving treatment outcomes in pets.
